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Mellitus: A Systematic Review and Meta-Analysis
Safi U. Khan, MD; Hammad Rahman, MD; Victor Okunrintemi, MD, MPH; Haris Riaz, MD; Muhammad Shahzeb Khan, MD;
Sudhakar Sattur, MD; Edo Kaluski, MD; A. Michael Lincoff, MD; Seth S. Martin, MD, MHS; Michael J. Blaha, MD, MPH
Background-—The relationship between lowering LDL (low-density lipoprotein) cholesterol with contemporary lipid-lowering
therapies and incident diabetes mellitus (DM) remains uncertain.
Methods and Results-—Thirty-three randomized controlled trials (21 of statins, 12 of PCSK9 [proprotein convertase subtilisin/
kexin type 9] inhibitors, and 0 of ezetimibe) were selected using Medline, Embase, and the Cochrane Central Register of Controlled
Trials (inception through November 15, 2018). A total of 163 688 nondiabetic patients were randomly assigned to more intensive
(83 123 patients) or less intensive (80 565 patients) lipid-lowering therapy. More intensive lipid-lowering therapy was defined as
the more potent pharmacological strategy (PCSK9 inhibitors, higher intensity statins, or statins), whereas less intensive therapy
corresponded to active control group or placebo/usual care of the trial. Metaregression and meta-analyses were conducted using a
random-effects model. No significant association was noted between 1-mmol/L reduction in LDL cholesterol and incident DM for
more intensive lipid-lowering therapy (risk ratio: 0.95; 95% CI, 0.87–1.04; P=0.30; R2=14%) or for statins or PCSK9 inhibitors. More
intensive lipid-lowering therapy was associated with a higher risk of incident DM compared with less intensive therapy (risk ratio:
1.07; 95% CI, 1.03–1.11; P<0.001; I2=0%). These results were driven by higher risk of incident DM with statins (risk ratio: 1.10;
95% CI, 1.05–1.15; P<0.001; I2=0%), whereas PCSK9 inhibitors were not associated with incident DM (risk ratio: 1.00; 95% CI,
0.93–1.07; P=0.96; I2=0%; P=0.02 for interaction).
Conclusions-—Among intensive lipid-lowering therapies, there was no independent association between reduction in LDL
cholesterol and incident DM. The risk of incident DM was higher with statins, whereas PCSK9 inhibitors had no association with
risk of incident DM. ( J Am Heart Assoc. 2019;8:e011581. DOI: 10.1161/JAHA.118.011581.)
Key Words: diabetes mellitus • LDL (low-density lipoprotein) cholesterol • PCSK9 (proprotein convertase subtilisin/kexin type 9)
• statin
L DL (low-density lipoprotein) cholesterol (LDL-C) is a well-established modifiable risk factor for clinical atheroscle-
rotic cardiovascular disease.1,2 Incremental reductions in
LDL-C levels by statins or intensifying statin therapy by
adding ezetimibe or PCSK9 (proprotein convertase subtilisin/
kexin type 9) have shown correspondingly higher cardiovas-
cular risk reductions.3–6 In contrast, several studies have
shown a significant association between statins and a higher
risk of incident diabetes mellitus (DM).7,8 However, this
association is not clear in case of PCSK9 inhibitors. The
FOURIER (Further Cardiovascular Outcomes Research with
PCSK9 Inhibition in Subjects with Elevated Risk) trial showed
nonsignificantly higher numbers of incident DM among
participants receiving evolocumab.9 Conversely, the ODYS-
SEY OUTCOMES (Alirocumab and Cardiovascular Outcomes
After Acute Coronary Syndrome) trial showed lesser risk of
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new onset of DM with alirocumab compared with placebo
(9.6% versus 10.1%).10 In a meta-analysis, exposure to LDL-
C–lowering alleles in or near NPC1L1 (Niemann-Pick C1-like 1)
or HMGCR (3-hydroxy-3-methylglutaryl-CoA reductase),
PCSK9, ABCG5/G8 (ATP-binding cassette subfamily G mem-
ber), and LDLR (LDL receptor), which encode the molecular
targets of lipid-lowering therapies (ie, statins, ezetimibe, and
PCSK9 inhibitors) were associated with higher risk of type 2
DM.11
Although the beneficial effects of LDL-C reduction on
cardiovascular outcomes are clearly established, the degree
of risk associated with reduction in LDL-C in terms of new-
onset DM is unclear,7,8 as is the potential heterogeneity of
this effect by LDL-C–lowering drug class. To assess whether
lowering LDL-C has any association with risk of incident DM
and whether this risk varies by different, established LDL-
C–lowering drugs, we performed a meta-analysis and
metaregression analysis.
Methods
Data Availability Statement
The authors declare that all supporting data are available
within the article (and its online supplementary files).
Data Sources and Searches
This systematic review and meta-analysis was conducted
according to Cochrane Collaboration guidelines12 and
reported in accordance with the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA) guide-
lines.13 Two authors (S.U.K. and H.R.) devised a broad search
strategy by using relevant keywords (statins, proprotein
convertase subtilisin/kexin type 9 inhibitors, PCSK9 inhibitors,
ezetimibe, low-density lipoprotein cholesterol, LDL-C, diabetes
mellitus; Table S1). We searched Medline (PubMed), Embase,
and the Cochrane Central Register of Controlled Trials from
the inception of the databases to November 15, 2018.
Although search restrictions were applied for clinical trials and
humans, no restrictions were applied for language, year of
publication, or text availability. Additional sources included
websites (European Society of Cardiology, https://www.esca
rdio.org/; American College of Cardiology, https://www.acc.
org and https://www.cardiosource.org; ClinicalTrialResults.
com, http://www.clinicaltrialresults.com/; ClinicalTrials.gov,
https://www.clinicaltrials.gov/), proceedings of major cardi-
ology meetings, and references of the relevant articles. The
citations were downloaded in Endnote X7 (Thompson ISI
Research Soft), and duplicates were identified and removed.
Two authors (M.S.K. and H.R.) independently screened the
records based on prespecified inclusion criteria. Any dis-
agreements were resolved by mutual consensus or third-party
review (S.U.K.).
Study Selection
The following prespecified inclusion criteria were used. First,
randomized controlled trials had to include at least 100
patients receiving the allocated pharmacological lipid-low-
ering therapy for a minimum of 12 weeks. Second, consis-
tent with former reports,1,2,6 we selected statin and nonstatin
therapies in combination with statin that lower LDL-C levels
via mechanisms that ultimately result in upregulation of LDL
receptor (R) expression (ezetimibe and PCSK9 inhibitors
[alirocumab and evolocumab]) compared with placebo or
active controls. Third, studies had to report at least 1 clinical
event for incident DM.
We excluded trials if (1) nonstatin therapy did not reduce
LDL-C levels primarily via upregulation of LDLR expression
(fibrates, niacin, and cholesteryl ester transfer protein
inhibitors), (2) interventions showed concomitant effect on
DM (bile acid sequestrants, ileal bypass surgery, exercise, and
diet),14–16 (3) findings of the study were reported as abstracts
and do not have subsequent full-text publication (risk of
having discrepancies between meeting abstract results and
full-text publication),17,18 and (4) trials assessing efficacy of
bococizumab, which is not a therapeutic option because of
immunogenicity.19
Clinical Perspective
What Is New?
• Statins and PCSK9 (proprotein convertase subtilisin/kexin
type 9) inhibitors reduce cardiovascular risk by reducing
LDL (low-density lipoprotein) cholesterol.
• Statins are known to increase the risk of incident diabetes
mellitus (DM), whereas randomized controlled trials have
shown numerically higher cases of incident DM with PCSK9
inhibitor therapy.
• It is not clearly known whether LDL cholesterol reduction is
associated with risk of incident DM and whether this risk
might vary across established LDL cholesterol–lowering
drugs.
What Are the Clinical Implications?
• This meta-analysis shows that among intensive lipid-
lowering drugs, there was no independent association
between LDL cholesterol reduction achieved by these
medications and risk of incident DM.
• The increased risk of incident DM was associated with
statins only; PCSK9 inhibitors did not show any association
with DM.
• The current study further adds to the safety of LDL
cholesterol lowering with regard to the risk of DM.
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Data Extraction and Quality Assessment
Data extraction was performed by 2 independent authors
(S.U.K. and H.R.) on a standard data collection form. The data
abstraction was based on baseline characteristics of partic-
ipants, treatment groups, events, total number of patients in
each group, diabetic patients in each group, nondiabetic
patients in each group (calculated as total patients minus
diabetic patients), baseline LDL-C and reduction in LDL-C in
each group, achieved LDL-C in each group and difference
between the groups, and follow-up duration of each trial. We
extracted data on incident DM using the methodology
reported in a former study, namely, if the trial had clearly
reported newly diagnosed DM as an adverse event or study
participants had commenced antidiabetic drug treatment
during the trial or if patients had 2 consecutive fasting blood
glucose levels ≥126 mg/dL during the study period.7
The absolute change in LDL-C was calculated as mean or
median difference, whichever was available, averaged over the
course of follow-up between 2 groups. If not reported, then the
achieved LDL-C value at the point closest to 50% of the median
follow-up was used.1 To assess the precision of calculated LDL-C
values, we compared our results with the Cholesterol Treat-
ment Trialists (CTT) collaboration meta-analysis20 and a meta-
analysis by Silverman et al.1 In older studies, for which LDL-C
was not available, we calculated the LDL-C from total
cholesterol using the following regression equation: LDL-C=
(total cholesterol)9[(total cholesterol)90.0012+0.3793].1
When available, we extracted data for intention to treat
analysis. Any discrepancy related to data was resolved by
discussion and referring to the original article. We also
reviewed prior systematic reviews and meta-analyses for any
additional information on the included studies in case the
authors had reported further data beyond published trials in
those meta-analyses.1,7,8 The Cochrane Collaboration tool for
bias risk assessment was used by 2 independent reviewers
(V.O. andM.S.K.) to assess the quality of each trial (Table S2).21
More intensive lipid-lowering therapy was defined as a more
potent pharmacological strategy, whereas less intensive lipid-
lowering therapy corresponded to placebo/usual care or the
active control group of the trial.2,6 The group allocation was
designated as such: (1) for statin versus placebo/usual care
trials, statin therapy belonged to the more intensive therapy
group and placebo/usual care was allocated to the less
intensive therapy arm; (2) for higher intensive versus lower
intensity statin trials, higher intensity statin was grouped with
more intensive lipid-lowering therapy and less intensive statin
was grouped with less intensive lipid-lowering therapy; and (3)
for PCSK9 inhibitor trials, PCSK9 inhibitor therapy was grouped
with more intensive lipid-lowering therapy and placebo/usual
care or active control (ezetimibe) was grouped with less
intensive lipid-lowering therapy.
Data Synthesis and Analysis
To account for potential between-study variance, estimates
were pooled using a DerSimonian and Laird random-effects
model.22 The principal summary statistic was risk ratio (RR),
supplemented by risk difference (RD) with 95% CI. Heterogene-
ity was assessed using Cochrane Q statistics and quantified by
I2 with values >25%, 50%, and 75% consistent with low,
moderate, and high degrees of heterogeneity, respectively.23
Publication bias was assessed using the funnel plot and Egger
regression test.24 Statistical significance was set at 5%.
Metaregression analyses were performed using random-
effects models with the restricted maximum likelihood
estimation. The Knapp and Hartung adjustment was applied
for calculation of standard errors of the estimated coefficients
to calculate summary effect estimates.25 Metaregression
analyses were conducted to estimate the associations among
absolute amount of reduction in LDL-C (calculated as the
difference in the achieved LDL-C between the 2 interven-
tions),1 percentage reduction in LDL-C (each 10%), baseline
LDL-C, and absolute reduction in LDL-C adjusted for baseline
LDL-C and incident DM. The index R2 value (defined as the
ratio of explained/total variance) was used to determine the
proportion of variance accounted for by the change in LDL-C.
Subgroup analyses were conducted according to weighted
between-group LDL-C differences observed at follow-up
across the trials for particular lipid-lowering strategies as
suggested by CTT collaboration meta-analysis20 and inter-
ventions: statins, PCSK9 inhibitors, statins versus no statins,
and high-intensity statins (atorvastatin 80 mg, simvastatin
80 mg, or rosuvastatin 40 mg) versus low-intensity statins
(lesser doses of corresponding statin therapy [atorvastatin
10 mg, simvastatin 20–40 mg, and rosuvastatin up to
20 mg]). Additional sensitivity analyses included meta-
analyses by fixed-effects model, analyses of trials with
sample sizes of ≥500 patients that reported outcomes at
follow-up ≥1 year, analyses according to year of publication,6
and trials with the same definition for DM. Analyses were
performed using Comprehensive Meta-Analysis software v3.0
(Biostat) and Metafor package v3.30 (R Project for Statistical
Computing).
Results
The initial electronic search yielded 3711 citations, of which
1400 studies were removed as duplicates. Of the remaining
2311 articles, 1970 citations were excluded at title- and
abstract-level screening. A total of 341 full-text articles were
considered relevant, of which 308 were excluded based on a
priori selection criteria. Ezetimibe data were presented as an
abstract at the European Society of Cardiology Congress
2015 in subgroup analysis of IMPROVE IT (Improved
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Reduction of Outcomes: Vytorin Efficacy International Trial),
which showed no significant association of ezetimibe plus
simvastatin versus simvastatin alone on incident DM (hazard
ratio: 1.04; P=0.46).26 This study was excluded based on a
priori selection criteria, that is, if findings of that study were
reported as abstracts and did not have subsequent full-text
publication, the study would be excluded because of risk of
discrepancies between abstract results and full-text publica-
tion. Ultimately, 33 trials met the criteria for the final list of
studies (Figure 1).
Twenty-one trials of statins (124 755 patients) and 12
trials of PCSK9 inhibitors (38 933 patients) reported incident
DM (Table 1).9,10,27–56 The pooled mean baseline LDL-C was
3.370.71 mmol/L, and mean follow-up duration was
4.21.2 years. A total of 163 688 nondiabetic patients were
randomly assigned to more intensive (83 123 patients) or
less-intensive (80 565 patients) lipid-lowering therapy. A total
of 9855 (6.0%) incident DM cases were reported in the total
study population. Additional characteristics of included trials
are reported in Table S3.
Metaregression analysis did not demonstrate significant
association between absolute reduction in LDL-C (for every
1 mmol/L) and incident DM for more intensive lipid-lowering
therapy (RR: 0.95; 95% CI, 0.87–1.04; P=0.30; R2=14%; RD:
0.002; 95% CI, 0.006 to 0.002; P=0.32; R2=0; Figure 2), for
statins (RR: 1.02; 95% CI, 0.91–1.14; P=0.67; R2=0; RD:
0.002; 95% CI, 0.007 to 0.003; P=0.44; R2=0), or for
PCSK9 inhibitors (RR: 1.09; 95% CI, 0.60–1.99; P=0.74; R2=0;
RD: 0.009; 95% CI,0.010 to 0.028; P=0.37; R2=0). This effect
remained consistent for change in baseline LDL-C values and
absolute reduction in LDL-C adjusted for baseline LDL-C
(Table 2). Similarly, more intensive lipid-lowering therapy (RR:
0.99; 95% CI, 0.97–1.01; P=0.48; R2=0; RD: 0.0002; 95% CI,
0.0001 to 0.0001; P=0.74; R2=0; Figure 3), statins (RR: 1.00;
95% CI, 0.99–1.00; P=0.18; R2=0; RD: 0.00007; 95% CI,
0.0001 to 0.0003; P=0.52; R2=0), or PCSK9 inhibitors (RR:
1.04; 95% CI, 0.98–1.11; P=0.12; R2=0.27; RD: 0.0007; 95%
CI, 0.0007 to 0.002; P=0.28; R2=0.59) showed consistent
nonsignificant association with risk of incident DM per 10%
reduction in LDL-C values.
Figure 1. Study selection according to Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines. CENTRAL indicates Cochrane Central Register of Controlled Trials; DM,
diabetes mellitus.
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In sensitivity analysis for trials with ≥500 patients and
follow-up ≥1 year, more intensive lipid-lowering therapy (RR:
0.96; 95% CI, 0.88–1.05; P=0.41; R2=16%; RD: 0.002; 95%
CI, 0.006 to 0.002; P=0.31; R2=0), statins (RR: 1.02; 95% CI,
0.91–1.13; P=0.64; R2=0; RD: 0.001; 95% CI, 0.007 to
0.003; P=0.49; R2=0), and PCSK9 inhibitors (RR: 0.77; 95% CI,
0.48–1.20; P=0.26; R2=0; RD: 0.001; 95% CI, 0.022 to
0.020; P=0.93; R2=0) were not significantly associated with
incident DM per 1-mmol/L decrease in LDL-C. Meta-analysis
stratified according to between-group difference LDL-C
achieved across lipid-lowering strategies did not show
significant association (P=0.07 for interaction; Figure 4).
Meta-analysis of the entire population showed that 6.1%
(5121/83 123) of patients had incident DM with the more
intensive lipid-lowering therapy versus 5.8% (4734/80 565)
with the less intensive lipid-lowering therapy. More intensive
lipid-lowering therapy was associated with a higher risk of
incident DM compared with less intensive therapy (RR: 1.07;
95% CI, 1.03–1.11; P<0.001; I2=0%; RD: 0.003; 95% CI,
0.001–0.006; P=0.002; I2=23%; Figure 5). These results were
Figure 2. Metaregression showing association of between-group differences in achieved LDL (low-density
lipoprotein) cholesterol (LDL-C) levels (mmol/L) and risk ratio of incident diabetes mellitus. Each trial is
represented by a data marker, the size of which is proportional to the weight in the metaregression. The
metaregression slope (predicted risk for degree of LDL-C reduction) is represented by a red line, and 95%
CIs are presented as dashed lines. The horizontal lines through each square represent 1 SE for the
associated absolute change in LDL-C, and the vertical line through each square represents the 95% CI for
relative risk. For converting millimoles to milligrams, multiply by 38.5. PCSK9 indicates proprotein
convertase subtilisin/kexin type 9.
Table 2. Metaregression Analyses for the Associations of LDL-C With Incident DM
Studies Patients
RR (95% CI)
Reduction of LDL-C,
per 1 mmol/L
Increase in Baseline
LDL-C, per 1 mmol/L
Reduction of LDL-C
Adjusted for Baseline LDL-C
Total population
More intensive lipid-lowering therapy 33 163 688 0.95 (0.87–1.04) 0.97 (0.91–1.03) 0.97 (0.87–1.07)
Statins 21 124 755 1.02 (0.91–1.14) 0.94 (0.88–1.01) 1.11 (0.98–1.28)
PCSK9 inhibitors 12 38 933 1.09 (0.60–1.99) 0.95 (0.62–1.43) 1.69 (0.71–4.05)
Trials with sample size of ≥500 patients which reported outcome at follow-up ≥1 y
More intensive lipid-lowering therapy 25 161 531 0.96 (0.88–1.05) 0.98 (0.91–1.03) 0.97 (0.87–1.07)
Statins 20 124 486 1.02 (0.91–1.13) 0.94 (0.88–1.01) 1.11 (0.99–1.28)
PCSK9 inhibitors 5 37 045 0.77 (0.48–1.20) 1.28 (0.65–2.53) 0.71 (0.44–1.15)
DM indicates diabetes mellitus; LDL-C, LDL (low-density lipoprotein) cholesterol; PCSK9, proprotein convertase subtilisin/kexin type 9; RR, risk ratio.
DOI: 10.1161/JAHA.118.011581 Journal of the American Heart Association 7
LDL-C Lowering and New Onset of Diabetes Mellitus Khan et al
S
Y
S
T
E
M
A
T
IC
R
E
V
IE
W
A
N
D
M
E
T
A
-A
N
A
L
Y
S
IS
D
ow
nloaded from
 http://ahajournals.org by on April 22, 2019
driven by higher risk of incident DM with statins (RR: 1.10;
95% CI, 1.05–1.15; P<0.001; I2=14%; RD: 0.004; 95% CI,
0.002–0.006; P=0.001; I2=13%), whereas PCSK9 inhibitors
were not associated with significant risk of incident DM (RR:
1.00; 95% CI, 0.93–1.07; P=0.96; I2=0%; RD: 0.001; 95% CI,
0.004 to 0.006; P=0.75; I2=11%; P=0.02 for interaction).
The higher risk of DM remained consistent when statins were
compared with no statins (RR: 1.09; 95% CI, 1.03–1.16;
P=0.01; I2=8%; RD: 0.003; 95% CI, 0.001–0.006; P=0.01;
I2=0%) or high-intensity statins versus low-intensity statins
(RR: 1.11; 95% CI, 1.03–1.19; P<0.001; I2=0%; RD: 0.009;
95% CI, 0.003–0.014; P=0.002; I2=16%; P=0.72 for interac-
tion; Figure 6). Sensitivity analysis for trials with ≥500
patients and follow-up ≥1 year showed consistent results
(P=0.03 for interaction; Figure 7). Meta-analysis according to
the fixed-effects model (Table S4) or sensitivity analyses
according to year of publication and definition of DM showed
consistent results (Table S5). The Egger regression test did
not detect publication bias (Figure S1).
Discussion
In this meta-analysis we report that over a mean follow-up
duration of 4 years, metaregression analysis did not show
significant association between reduction in LDL-C by more
intensive lipid-lowering therapy and risk of incident DM. The 7%
RR and 0.3% absolute risk of incident DM across more intensive
lipid-lowering strategy was driven by 10% higher RR and 0.4%
absolute risk with statins. Conversely, PCSK9 inhibitors in the
setting of background statin therapy were not associated with
significant risk of incident DM. These results suggest that
among the intensive lipid-lowering strategies, the modest risk
of incident DM may be prominent with statins only.
Statin-induced DM is a much discussed phenomenon.7,8,57
The JUPITER (Justification for the Use of Statins in Prevention:
an Intervention Trial Evaluating Rosuvastatin) trial showed a
25% increase in incident DM (physician reported) over a median
follow-up of 1.9 years with rosuvastatin 20 mg compared with
placebo.58 This conclusion was also supported by Sattar and
colleagues (13 trials, 91 140 patients), showing 9% increased
relative risk of incident DM with statins over a mean duration of
4 years,8 and Preiss et al in their comparison of more intensive
statin therapy with moderate-intensity statin therapy.7
The exact mechanism of statin-inducedDM remains unclear,
and various mechanisms have been postulated to explain this
association. First, statins may derange the glucose metabolism
by negative effects on both b-cell secretion and insulin
sensitivity. For example, the METSIM (Metabolic Syndrome in
Men) study (9749 patients) showed 46% increased relative risk
of type 2 DM, 24% reduction in insulin sensitivity, and 12%
Figure 3. Metaregression showing association between percentage reduction of LDL (low-density
lipoprotein) cholesterol (LDL-C) in the active arm and relative risk of incident diabetes mellitus. Each trial is
represented by a data marker, the size of which is proportional to the weight in the metaregression. The
metaregression slope (predicted risk for degree of LDL-C reduction) is represented by a red line, and 95%
CIs are presented as dashed lines. The horizontal lines through each square represent 1 SE for the
associated absolute change in LDL-C, and the vertical line through each square represents the 95% CI for
relative risk.
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reduction in insulin secretion in patients taking statins.59 It is
proposed that b-cell dysfunction might be related to LDLR-
mediated increased levels of intracellular cholesterol. Studies
with murine experimental models have shown that the addition
of LDL-C to culture medium of rat islet b cells resulted in cell
death.60,61 To further explore this concept, Besseling et al
conducted a study in patients with familial hypercholesteremia
(63 320 patients) and showed that prevalence of type 2 DM
was significantly lower in familial hypercholesteremia patients
than unaffected relatives (1.75% versus 2.93%, P<0.001).62
Hypercholesteremia in familial hypercholesteremia is caused
by genetically impaired LDLR-mediated transcellular choles-
terol transport, whereas, conversely, HMGCR inhibition by
statins promotes transmembranous cholesterol uptake by
increasing expression of LDLR; therefore, the authors proposed
that there might be a causal relationship between LDLR-
mediated increased internalization of cholesterol into pancre-
atic b cells and impaired insulin secretion.62
Second, animal studies have suggested that statin-induced
myopathy occurs because of development of muscle insulin
resistance63; using this evidence, Preiss et al hypothesized
that the risk might be related to the effect of statins on insulin
sensitivity in muscle and liver.7
Third, weight gain may play a causal role in development of
DM by increasing insulin resistance. Swerdlow et al studied
single-nucleotide polymorphism in HMGCR genes and used
rs17238484 and rs12916 as proxies for HMGCR inhibition by
statins.57 This meta-analysis of 43 genetic studies (223 463
patients) showed that these HMGCR single-nucleotide poly-
morphisms were associated with higher body weight, waist
circumference, lower LDL-C, and increased plasma glucose
concentration.
Finally, genetic data have shown a potential association
between LDL-C lowering and incident DM. Lotta et al
demonstrated that LDL-C–lowering alleles in or near HMGCR
were associated with higher risk of type 2 DM (odds ratio:
1.39; P=0.03).11 Although the possibility of other mechanisms
cannot be excluded, the pooled analyses of randomized
controlled trials could not strongly demonstrate an associa-
tion between lowering LDL-C and incident DM.8,64
Figure 4. Forestplot showingsubgroupanalysisaccording toweightedbetween-groupdifference inLDL (low-density lipoprotein) cholesterol (LDL-
C) achieved (mmol/L) among interventions and risk of incident diabetes mellitus. PCSK9 indicates proprotein convertase subtilisin/kexin type 9.
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Lotta and colleagues reported that genetic variants in
PCSK9 were associated with a 19% (95% CI, 2–38%) higher RR
for DM per 1-mmol/L reduction in LDL-C.11 On the same
note, PCSK9 inhibitor trials also hinted at a potential
association of PCSK9 inhibitors with new-onset DM. In
FOURIER, the risk of incident DM was numerically higher
Figure 5. Forest plot comparing risk of incident diabetes mellitus among interventions. PCSK9 indicates proprotein
convertase subtilisin/kexin type 9.
Figure 6. Sensitivity analysis, forest plot showing subgroup analysis of statin therapy on incident diabetes mellitus.
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with PCSK9 inhibitors (hazard ratio: 1.05; P=0.34).9 However,
in a prespecified analysis of the FOURIER trial, evolocumab
did not increase the risk of new-onset DM in nondiabetic
patients (hazard ratio: 1.05; 95% CI, 0.94–1.17) or those with
prediabetes (hazard ratio: 1.00; 95% CI, 0.89–1.13).65 Sim-
ilarly, the ODYSSEY OUTCOME trial showed fewer participants
with incident DM with PCSK9 inhibitor use compared with
placebo.10
We critically compared our results with prior meta-
analyses. Sattar and colleagues showed significantly higher
risk of incident DM with statins, but metaregression analysis
did not demonstrate an association between change in LDL-C
and risk of incident DM.8 Meta-analysis by Preiss et al (5
statin trials, 32 752 patients) showed 12% relative risk of
incident DM with intensive-dose statin therapy compared with
moderate-dose statin therapy.7 De Carvalho et al meta-
analyzed 20 randomized controlled trials (68 123 patients)
of PCSK9 therapy to investigate its association with incident
type 2 DM.66 They reported that during a median follow-up of
78 weeks, PCSK9 inhibitors increased fasting blood glucose
by 1.88 mg/dL and HbA1c by 0.032%; however, this effect
did not translate into increased incidence of DM (RR: 1.04;
P=0.42). In a metaregression analysis, they showed a 3.8%
increase in DM for each 10% lowering of LDL-C levels;
however, this study included the SPIRE trial, which does not
reflect contemporary PCSK9 inhibitor therapy. Conversely,
findings of Cao et al were consistent with our outcomes.64
Both studies were published before ODYSSEY OUTCOMES
and thus lacked this large data set.10 To our knowledge, our
current study is the largest updated meta-analysis that, in
addition to systematically evaluating the association of LDL-C
reduction with incident DM, has quantitatively compared the
effects of statins and PCSK9 inhibitors to provide a more
comprehensive overview of this issue.
The current study is subject to limitations. First, this study is a
trial-level meta-analysis, and given lack of access to the individual
patient data, we could not adjust our analysis for various
comorbidities and baseline characteristics such as age, body
mass index, baseline fasting blood glucose level, or HbA1c.
Therefore, a patient-level meta-analysis could provide more
valuable information to further evaluate such associations.
Second, PCSK9 inhibitors were conducted in the background of
statins. Third, it is important to note that the definition of incident
DM was not uniform across the trials. Specifically, most trials
reported nonadjudicated outcomes of incident DM; however, we
tried to compensate for this by performing sensitivity analyses.
Fourth, we could not detect publication bias; that said, because of
exclusion of a notable number of trials that did not report incident
Figure 7. Sensitivity analysis, forest plot comparing risk of incident diabetes mellitus among interventions in trials with sample sizes ≥500
patients and follow-up ≥1 year. PCSK9 indicates proprotein convertase subtilisin/kexin type 9.
DOI: 10.1161/JAHA.118.011581 Journal of the American Heart Association 11
LDL-C Lowering and New Onset of Diabetes Mellitus Khan et al
S
Y
S
T
E
M
A
T
IC
R
E
V
IE
W
A
N
D
M
E
T
A
-A
N
A
L
Y
S
IS
D
ow
nloaded from
 http://ahajournals.org by on April 22, 2019
DM, a certain degree of publication bias could not be completely
excluded. Finally, like any meta-analysis, this report is limited by
heterogeneity inbaselinecharacteristics, sample sizes, drugs,and
durations of studies. Nevertheless, the results had low statistical
heterogeneity, andwetried tocompensate forvariability insample
size and follow-up duration through sensitivity analysis.
In conclusion, the current study does not demonstrate an
association between degree of LDL-C lowering by contempo-
rary lipid-lowering therapies and risk of incident DM. Among
intense lipid-lowering therapies, the risk of DM was higher
with statins only, whereas PCSK9 inhibitors (in setting of
background statin therapy) did not show a significant
association with incident DM.
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Table S1. Search strategy.  
 
 
 
Search String ("hydroxymethylglutaryl-coa reductase inhibitors"[Pharmacological 
Action] OR "hydroxymethylglutaryl-coa reductase inhibitors"[MeSH 
Terms] OR ("hydroxymethylglutaryl-coa"[All Fields] AND 
"reductase"[All Fields] AND "inhibitors"[All Fields]) OR 
"hydroxymethylglutaryl-coa reductase inhibitors"[All Fields] OR 
"statins"[All Fields]) OR (("proprotein convertases"[MeSH Terms] OR 
("proprotein"[All Fields] AND "convertases"[All Fields]) OR 
"proprotein convertases"[All Fields] OR ("proprotein"[All Fields] AND 
"convertase"[All Fields]) OR "proprotein convertase"[All Fields]) AND 
subtilisin/kexin[All Fields] AND type[All Fields] AND 9[All Fields] 
AND ("antagonists and inhibitors"[Subheading] OR ("antagonists"[All 
Fields] AND "inhibitors"[All Fields]) OR "antagonists and 
inhibitors"[All Fields] OR "inhibitors"[All Fields])) OR (pcsk[All Fields] 
AND 9[All Fields] AND ("antagonists and inhibitors"[Subheading] OR 
("antagonists"[All Fields] AND "inhibitors"[All Fields]) OR "antagonists 
and inhibitors"[All Fields] OR "inhibitors"[All Fields])) OR 
("ezetimibe"[MeSH Terms] OR "ezetimibe"[All Fields]) AND 
("cholesterol, ldl"[MeSH Terms] OR ("cholesterol"[All Fields] AND 
"ldl"[All Fields]) OR "ldl cholesterol"[All Fields] OR ("low"[All Fields] 
AND "density"[All Fields] AND "lipoprotein"[All Fields] AND 
"cholesterol"[All Fields]) OR "low density lipoprotein cholesterol"[All 
Fields]) OR ldl-c[All Fields] AND ("diabetes mellitus"[MeSH Terms] 
OR ("diabetes"[All Fields] AND "mellitus"[All Fields]) OR "diabetes 
mellitus"[All Fields]) 
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Table S2. Cochrane Quality risk assessment. 
Studies Randomization Allocation 
concealment 
Blinding 
(Physician/Patient) 
Adjudication 
of outcomes 
Selective 
outcome 
reporting 
Incomplete data 
reporting 
addressed? 
Free of other 
bias? 
Statins 
PMSGCRP (1993)1 Low risk Moderate risk Low risk Moderate risk Low risk Low risk Low risk 
4S (1994)2 Low risk Moderate risk Low risk Low risk Low risk Low risk Low risk 
WOSCOP (1995)3 Low risk Moderate risk Low risk Low risk Low risk Low risk Low risk 
LIPID (1998)4 Low risk Moderate risk Low risk Low risk Low risk Low risk Low risk 
AFCAPS/TexCAPS (1998)5 Low risk Moderate risk Low risk Low risk Low risk Low risk Low risk 
GISSI PREV (2000)6 Moderate risk Moderate risk High risk Moderate risk Low risk Moderate risk Moderate risk 
ALLHAT-LLT (2002)7 Low risk Low risk High risk Low risk Low risk Moderate risk Moderate risk 
GREACE (2002)8 Low risk Moderate risk High risk Low risk Low risk Low risk Low risk 
PROSPER (2002)9 Low risk Low risk Low risk Low risk Low risk Moderate risk Low risk 
HPS (2003)10 Low risk Moderate risk Low risk Low risk High risk Low risk Moderate risk 
ASCOT-LLA (2003)11 Low risk Moderate risk Low risk Moderate risk Low risk Low risk Moderate risk 
A to Z (2004)12 Low risk Moderate risk Low risk Low risk Low risk Low risk Low risk 
PROVE IT (2004)13 Low risk Moderate risk Low risk Low risk Low risk Low risk Low risk 
IDEAL (2005)14 Moderate risk Low risk High risk Low risk Low risk Low risk Moderate risk 
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TNT (2005)15 Moderate risk Moderate risk Low risk Low risk Low risk Low risk Low risk 
MEGA (2006)16 Low risk Moderate risk High risk Low risk High risk Low risk Low risk 
CORONA (2007)17 Low risk Low risk Low risk Low risk Low risk Low risk Low risk 
GISSI-HF (2008)18 Low risk Low risk Low risk Low risk Low risk Low risk Low risk 
JUPITER (2008)19 Moderate risk Low risk Low risk Low risk Low risk Moderate risk Low risk 
ASTRONOMER (2010)20 Low risk Low risk Low risk Moderate risk Low risk Low risk Low risk 
SEARCH (2010)21 Low risk Low risk Low risk Low risk Low risk Low risk Low risk 
PCSK 9 inhibitors 
ODYSSEY OPTION I (2015)22 Moderate risk Moderate risk Low risk Low risk Low risk Low risk Low risk 
ODYSSEY FH I (2015)23  Moderate risk Moderate risk Low risk Low risk Low risk Low risk Low risk 
ODYSSEY FH II (2015)23 Moderate risk Moderate risk Low risk Low risk Low risk Low risk Low risk 
ODYSSEY LONG TERM 
(2015)24 
Low risk Low risk Low risk Low risk Low risk Low risk Low risk 
OSLER (2015)25 Moderate risk Moderate risk Low risk Low risk Low risk Low risk Low risk 
GLAGOV (2016)26 Moderate risk Moderate risk Low risk Low risk Low risk Low risk Low risk 
ODYSSEY CHOICE I (2016)27 Low risk Moderate risk Low risk Low risk Low risk Moderate risk Low risk 
ODYSSEY JAPAN (2016)28 Low risk Moderate risk Moderate risk Low risk Low risk Low risk Low risk 
YUKAWA-2 (2016)29 Low risk Moderate risk Moderate risk Low risk Low risk Low risk Low risk 
ODYSSEY OPTION II (2016)30 Low risk Low risk Low risk Low risk Low risk Low risk Low risk 
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FOURIER (2017)31 Low risk Low risk Low risk Low risk Low risk Low risk Low risk 
ODYSSEY OUTCOMES 
(2018)32 
Low risk Low risk Low risk Low risk Low risk Moderate risk Low risk 
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Table S3. Baseline characteristics of the entire study population for each trial. 
 
Studies (Year) N Groups Age 
(years) 
Men (%) Coronary heart 
disease (%) 
Hypertension 
(%) 
Smoking (%) 
PMSGCRP (1993)1 1,062 Pravastatin 20 mg 55 77 32 47 28 
Placebo 55 76 36 48 30 
4S (1994)2 4,444 Simvastatin 20-40 mg 58.6 82 100 26 24 
Placebo 58.6 81 100 26 27 
WOSCOPS (1995)3 6,595 Pravastatin 40 mg 55.3 100 0.0 16 44 
Placebo 55.1 100 0.0 15 44 
LIPID (1998)4 9,014 Pravastatin 40 mg 62 83 100 41 9 
Placebo 62 83 100 42 10 
AFCAPS/TexCAPS 
(1998)5 
6,605 Lovastatin 20-40 mg 58 85 0.0 22 13 
Placebo 58 85 0.0 22 12 
GISSI PREV  
(2000)6 
3, 460 Pravastatin 20 mg 59.3 86.3 ─ 36.5 11.8 
Usual care 
ALLHAT-LLT 
(2002)7 
10,355 Pravastatin 40 mg 66.4 51.4 13.4 89.8 23.1 
Usual care 66.3 51.0 15.0 89.9 23.3 
GREACE (2002)8 1,600 Atorvastatin 80 mg 58 78 100 42 NR 
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Usual care 59 79 100 44 NR 
PROSPER (2002)9 5,804 Pravastatin 40 mg 75.4 48.3 45.2 62.2 26.0 
Placebo 75.3 48.3 43.2 61.6 27.6 
HPS (2003)10 
20,536 Simvastatin 40 mg 87 86 87 ─ ─ 
Placebo 23 18 22 ─ ─ 
ASCOT-LLA 
(2003)11 
10,342 Atorvastatin 10 mg 63.1 81.1 0.0 ─ 33.2 
Placebo 63.2 81.3 0.0 ─ 32.2 
A to Z (2004)12 4,497 Simvastatin 20mg 61 75 16 50 41 
Simvastatin 40/80 mg 61 76 18 50 41 
PROVE IT (2004)13 4,162 Pravastatin 40 mg 58.3 78.4 100 49.2 37.1 
Atorvastatin 80 mg 58.1 77.8 100 51.3 36.4 
IDEAL (2005)14 8,888 Simvastatin 20 mg 61.6 80.8 100 33.0 21.2 
Atorvastatin 80 mg 61.8 80.9 100 32.9 20.1 
TNT (2005)15 10,001 Atorvastatin 80 mg 61.2 81.2 100 53.9 13.4 
Atorvastatin 10 mg 60.9 80.8 100 54.4 13.4 
MEGA (2006)16 7,832 Pravastatin 10-20 mg 58.2 32 0.0 42 21 
Usual care 58.4 31 0.0 42 20 
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CORONA (2007)17 5,011 Rosuvastatin 10 mg 73 76 100 63 9 
Placebo 73 76 100 63 8 
GISSI-HF (2008)18 4,631 Rosuvastatin 10 mg 68 76.2 31.8 55.1 14.1 
Placebo 68 78.6 33.8 53.5 14.0 
JUPITER (2008)19 17,802 Rosuvastatin 20 mg 66 5474 0.0  ─ ─ 
Placebo 66 5527 0.0 ─ ─ 
ASTRONOMER 
(2010)20 
269 Rosuvastatin 40 mg 58.0 60.5 0.0 ─ 11.2 
Placebo 57.9 63.0 0.0 ─ 10.4 
SEARCH (2010)21 12,064 Simvastatin 80 mg 64 (9) 
 
83 100 
 
42 30 
Simvastatin 20 mg 
ODYSSEY 
OPTIONS I 
(2015)22 
355 Alirocumab 75/150 mg 
every 2 weeks 
63.1 61.5 52.9 76.9 ─ 
Ezetimibe 62.8 66.5 57.8 78.9 ─ 
ODYSSEY FH I 
(2015)23 
486 Alirocumab 75 mg every 2 
weeks 
52.1 180 147 139 39 
Placebo 51.7 94 78 71 30 
ODYSSEY FH II 
(2015)23 
249 Alirocumab 75 mg every 2 
weeks 
53.2 86 58 57 36 
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Placebo 53.2 45 31 24 13 
ODYSSEY LONG 
TERM (2015)24 
2,341 Alirocumab 150 mg every 2 
weeks 
60.4 983 1055 ─ 325 
Placebo 60.6 474 552 ─ 159 
OSLER (2015)25 
4,465 Evolocumab 140 mg every 
2 weeks or 420 mg monthly 
57.8 1490 589 1545 465 
Placebo 58.2 765 307 777 222 
GLAGOV (2016)26 968 Evolocumab 420 mg 
monthly 
59.8 349 484 398 124 
Placebo 59.8 350 484 405 113 
ODYSSEY 
CHOICE I (2016)27 
   803 Alirocumab 300 mg 
monthly or 75 mg every 2 
weeks 
59.2 80 40 ─ ─ 
Placebo 59.4 40 20 ─ ─ 
ODYSSEY JAPAN 
(2016)28 
206 Alirocumab 150 mg every 2 
weeks 
60.3 84 18 ─ ─ 
Placebo 61.8 47 8 ─ ─ 
YUKAWA-2 
(2016)29 
404 Evolocumab 140 mg every 
2 weeks or 420 mg monthly  
62.0 60 15 75 23 
Placebo  61.0   61 11 72 26 
D
ow
nloaded from
 http://ahajournals.org by on April 22, 2019
 
 
ODYSSEY 
OPTIONS II 
(2016)30 
305 Alirocumab 75 mg every 2 
weeks 
59.9 57 53 74 ─ 
Usual care 61.3  63 60 72 ─ 
FOURIER (2017)31 27,564 Evolocumab 140 mg every 
2 weeks or 420 mg monthly 
62.5 75.4 80.9 80.1 28.0 
Placebo 62.5 75.5 81.3 80.1 28.5 
ODYSSEY 
OUTCOMES 
(2018)32 
18,924 Alirocumab 75-150 mg 
every 2 weeks 
58.5 74.7 100 65.6 24.1 
Placebo 58.6 74.9 100 63.9 24.1 
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Table S4. Analyses According to Fixed Effects Model.  
Analysis Studies Patients RR [95% CI] P-interaction 
Risk of Incident DM in Total Population  
More intensive lipid lowering therapy 33 163,688 1.07 [1.03, 1.11]  
0.02 Statins 21 124,755 1.10 [1.05, 1.15] 
PCSK9 Inhibitors 12 38,933 1.00 [0.93, 1.07] 
Subgroup Analysis According to Weighted Between-Group Difference in LDL-C Achieved 
0.51 mmol/L 5 32,752 1.11 [1.03, 1.19]  
0.08 1.15 mmol/L 16 92,003 1.09 [1.03, 1.16] 
1.58 mmol/L 12 38,933 1.00 [0.93, 1.07] 
Sensitivity Analysis According to Statins Subgroups 
High intensity statin versus low intensity statin 5 32,752 1.11 [1.03, 1.19] 0.72 
Statin vs no statin 16 92,003 1.09 [1.03, 1.16] 
Trials with sample size of ≥ 500 patients which reported outcome at follow-up ≥ 1 year 
More intensive lipid lowering therapy 25 161,531 1.07 [1.03, 1.11]  
0.03 Statins 20 124,486 1.10 [1.05, 1.15] 
PCSK9 Inhibitors 5 37,045 1.00 [0.93, 1.08] 
*P-interaction corresponds to statin and PCSK9 inhibitor subgroup interaction   
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Table S5. Sensitivity Analyses According to Year of Publication and Definition of Diabetes Mellitus. 
   Risk Ratio [95% CI]  
 Studies Patients More intensive lipid lowering 
therapy 
Statin PCSK9 Inhibitor *P interaction  
Cumulative Meta-Analysis Accounting for the Year of the Trial Publication 
Original meta-analysis 33 163,688 1.07 [1.03, 1.11] 1.10 [1.05, 1.15] 1.00 [0.93, 1.07] 0.02 
4S and WOSCOPS excluded 31 153,472 1.08 [1.04, 1.12] 1.11 [1.06, 1.17] 1.00 [0.93, 1.07] 0.01 
Year before 2000 excluded 28 139,202 1.08 [1.04, 1.13] 1.13 [1.07, 1.18] 1.00 [0.93, 1.07] 0.006 
Year before 2010 excluded 14 49,999 1.02 [0.96, 1.08] 1.07 [0.96, 1.19] 1.00 [0.93, 1.07] 0.31 
Meta-Analysis Stratified According to Definition of Diabetes Mellitus 
Two FBG levels ≥ 126 mg/dL 11 89,303 1.10 [1.04, 1.16] 1.11 [1.05, 1.18] 1.05 [0.95, 1.17] 0.37 
Medication/Adverse events 14 45,625 1.07 [0.97, 1.18] 1.08 [0.98, 1.19] 0.96 [0.61, 1.51] 0.62 
Adverse events only 8 28,760 1.00 [0.92, 1.08] 1.08 [0.95, 1.23] 0.95 [0.86, 1.05] 0.12 
*P-interaction corresponds to statin and PCSK9 inhibitor subgroup interaction. FBG (Fasting Blood Glucose) 
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Figure S1. Funnel plot for publication bias assessment. 
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